Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Pasquale Rescigno, Núria Porta, Laura Finneran, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Penny Flohr, Susana Miranda, Cláudia Bertan, Ana Ferreira, Mateus Crespo, Daniel Nava Rodrigues, Bora Gürel, Jenny Nobes, Simon J. Crabb, Zafar Malik, Christy Ralph, Ursula McGovern, Peter Hoskin, Robert J. Jones, Alison Birtle, Joanna Gale, Peter Sankey, Suneil Jain, Duncan B. McLaren, E. Chadwick, Aude Espinasse, Emma Hall, Johann S. de Bono